Companies › Diakonos Oncology
3 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DOC1021 Double-loaded dendritic cell vaccine loaded with tumor lysate and mRNA | – | Phase 2 | Glioblastoma (GBM); Refractory Melanoma | Mar 2030 |
| Peginterferon Alfa-2A Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | Glioblastoma (GBM) | Mar 2030 |
| Autologous DC Therapy Th-1 dendritic cell immunotherapy | – | Phase 1 | Pancreatic Adenocarcinoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04157127 | Autologous DC Therapy | Phase 1 | Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT06805305 | DOC1021 | Phase 2 | Glioblastoma (GBM) | Oncology | Mar 2030 |
| NCT06805305 | Peginterferon Alfa-2A | Phase 2 | Glioblastoma (GBM) | Oncology | Mar 2030 |
| NCT07288112 | DOC1021 | Phase 1 | Refractory Melanoma | Oncology | Jan 2031 |
PharmaEssentia BriaCell Therapeutics Brii Biosciences Xiamen Amoytop Biotech Biogen AstraZeneca Genrix (Shanghai) Biopharmaceutical
Allotera Therapeutics HRYZ Biotech Scancell Guangzhou Virotech Pharmaceutical PharmaEssentia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.